Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone

Simple item page
dc.citation.firstpage312
dc.citation.issueNumber3
dc.citation.journalTitleACS Central Science
dc.citation.lastpage321
dc.citation.volumeNumber8
dc.contributor.authorTian, Zeru
dc.contributor.authorYu, Chenfei
dc.contributor.authorZhang, Weijie
dc.contributor.authorWu, Kuan-Lin
dc.contributor.authorWang, Chenhang
dc.contributor.authorGupta, Ruchi
dc.contributor.authorXu, Zhan
dc.contributor.authorWu, Ling
dc.contributor.authorChen, Yuda
dc.contributor.authorZhang, Xiang H.-F.
dc.contributor.authorXiao, Han
dc.date.accessioned2022-04-28T14:29:01Z
dc.date.available2022-04-28T14:29:01Z
dc.date.issued2022
dc.description.abstractDespite the rapid evolution of therapeutic antibodies, their clinical efficacy in the treatment of bone tumors is hampered due to the inadequate pharmacokinetics and poor bone tissue accessibility of these large macromolecules. Here, we show that engineering therapeutic antibodies with bone-homing peptide sequences dramatically enhances their concentrations in the bone metastatic niche, resulting in significantly reduced survival and progression of breast cancer bone metastases. To enhance the bone tumor-targeting ability of engineered antibodies, we introduced varying numbers of bone-homing peptides into permissive sites of the anti-HER2 antibody, trastuzumab. Compared to the unmodified antibody, the engineered antibodies have similar pharmacokinetics and in vitro cytotoxic activity, but exhibit improved bone tumor distribution in vivo. Accordingly, in xenograft models of breast cancer metastasis to bone sites, engineered antibodies with enhanced bone specificity exhibit increased inhibition of both initial bone metastases and secondary multiorgan metastases. Furthermore, this engineering strategy is also applied to prepare bone-targeting antibody–drug conjugates with enhanced therapeutic efficacy. These results demonstrate that adding bone-specific targeting to antibody therapy results in robust bone tumor delivery efficacy. This provides a powerful strategy to overcome the poor accessibility of antibodies to the bone tumors and the consequential resistance to the therapy.
dc.identifier.citationTian, Zeru, Yu, Chenfei, Zhang, Weijie, et al.. "Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone." <i>ACS Central Science,</i> 8, no. 3 (2022) American Chemical Society: 312-321. https://doi.org/10.1021/acscentsci.1c01024.
dc.identifier.digitalacscentsci-1c01024
dc.identifier.doihttps://doi.org/10.1021/acscentsci.1c01024
dc.identifier.urihttps://hdl.handle.net/1911/112182
dc.language.isoeng
dc.publisherAmerican Chemical Society
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleBone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone
dc.typeJournal article
dc.type.dcmiText
dc.type.publicationpublisher version
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
acscentsci-1c01024.pdf
Size:
6.3 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
Bioengineering Publications
BioSciences Publications
Chemistry Publications